论文部分内容阅读
为探讨cyclinD1基因扩增的临床意义，采用免疫荧光技术检测了25例喉鳞癌的新鲜标本。发现细胞周期蛋白D1基因（cyclinD1基因）在喉癌中有9例扩增（占37％），而且与肿瘤分级和TNM分期差别无显著性意义（P＞0．05）；而与肿瘤组织相邻的正常组织表达阴性，或仅见极个别散在表达，推测cyclinD1基因在喉癌的发生发展中可能是非早期现象。通过跟踪的调查发现，在cyclinD1基因表达阳性的肿瘤9例中，有4例复发；而cyclinD1基因表达阴性的肿瘤16例中，仅1例复发，二者差别有显著意义（P＜0．05）。所以cyclinD1基因的扩增可望作为一种新的预后标志。
To investigate the clinical significance of cyclinD1 gene amplification, 25 samples of laryngeal squamous cell carcinoma were detected by immunofluorescence technique. It was found that there were 9 cases of cyclinD1 gene amplification in laryngeal carcinoma (37%), but no significant difference with tumor grade and TNM stage (P> 0.05) Opposite normal tissue expression negative, or only a very small number of scattered expression speculated that cyclinD1 gene in the development of laryngeal cancer may be non-early phenomenon. The follow-up survey found that among the 9 cases with positive expression of cyclinD1 gene, 4 cases relapsed; only 1 of the 16 cases with cyclinD1 negative expression had recurrence, the difference was significant (P <0.05 ). So cyclinD1 gene amplification is expected as a new prognostic marker.